drugset / Trial / NCT04707573

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

NCT04707573

Phase 2 Completed 22 enrolled Akebia Therapeutics
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study was conducted to assess the pharmacokinetic (PK) profile, safety, and tolerability in participants with Stage 3 and 4 Chronic Kidney Disease (CKD) following a single oral dose of Vadadustat.

Timeline

Start
2010-07-08
Primary completion
2010-09-24
Completion
2010-09-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Vadadustat Small molecule 500 mg Oral